Impaired activation of lesional CD8+ T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis

Mukherjee, Shibabrata ; Sengupta, Ritika ; Mukhopadhyay, Debanjan ; Braun, Claudia ; Mitra, Sneha ; Roy, Susmita ; Kanti Das, Nilay ; Chatterjee, Uttara ; von Stebut, Esther ; Chatterjee, Mitali (2019) Impaired activation of lesional CD8+ T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis Scientific Reports, 9 (1). ISSN 2045-2322

[img] PDF
15MB

Official URL: http://doi.org/10.1038/s41598-018-37144-y

Related URL: http://dx.doi.org/10.1038/s41598-018-37144-y

Abstract

Post Kala-azar dermal leishmaniasis (PKDL), caused by Leishmania donovani is the dermal sequel of Visceral Leishmaniasis and importantly, is the proposed disease reservoir. The survival of Leishmania parasites within monocytes/macrophages hinges on its ability to effectively nullify immune activation mechanisms. Thus, delineating the disease-promoting immune mechanisms can facilitate development of immunotherapeutic strategies. Accordingly, in the absence of an animal model, this study aimed to delineate the status of CD8+ T-cells in patients with PKDL. At disease presentation, the absence of CD4+ T-cells at lesional sites was concomitant with an overwhelming infiltration of CD8+ T-cells that demonstrated an absence of Perforin, Granzyme and Zap-70, along with an enhanced expression of Programmed Death-1 (PD-1) and the skin-homing CCL17. Additionally, the lesional CCR4+CD8+ population was associated with an enhanced expression of IL-10 and IL-5. In circulation, the enhanced CD8+CCR4+ T-cell population and raised levels of CCL17/22 was associated with an increased frequency of PD-1, while CD127 was decreased. Taken together, in PKDL, the enhanced plasma and lesional CCL17 accounted for the dermal homing of CD8+CCR4+ T-cells, that along with a concomitant upregulation of PD-1 and IL-10 mediated immune inactivation, emphasizing the need for designing immunotherapies capable of reinvigorating T-cell potency.

Item Type:Article
Source:Copyright of this article belongs to Springer Nature Limited
ID Code:132970
Deposited On:23 Dec 2022 10:02
Last Modified:23 Dec 2022 10:02

Repository Staff Only: item control page